Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease

      research-article
      a , b , * , c , b , b , b , b , d , c , e , f , * , for the Parkinson’s Progression Markers Initiative
      Journal of Parkinson's Disease
      IOS Press
      DaTScan, motor, non-motor, Parkinson’s disease, sex

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Investigation of sex-related motor and non-motor differences and biological markers in Parkinson’s disease (PD) may improve precision medicine approach.

          Objective:

          To examine sex-related longitudinal changes in motor and non-motor features and biologic biomarkers in early PD.

          Methods:

          We compared 5-year longitudinal changes in de novo, untreated PD men and women (at baseline N = 423; 65.5%male) of the Parkinson’s Progression Markers Initiative (PPMI), assessing motor and non-motor manifestations of disease; and biologic measures in cerebrospinal fluid (CSF) and dopamine transporter deficit on DaTscan TM uptake.

          Results:

          Men experienced greater longitudinal decline in self-reported motor ( p < 0.001) and non-motor ( p = 0.009) aspects of experiences of daily living, such that men had a yearly increase in MDS-UPDRS part II by a multiplicative factor of 1.27 compared to women at 0.7, while men had a yearly increase in MDS-UPDRS part I by a multiplicative factor of 0.98, compared to women at 0.67. Compared to women, men had more longitudinal progression in clinician-assessed motor features in the ON medication state ( p = 0.010) and required higher dopaminergic medication dosages over time ( p = 0.014). Time to reach specific disease milestones and longitudinal changes in CSF biomarkers and DaTscan TM uptake were not different by sex.

          Conclusion:

          Men showed higher self-assessed motor and non-motor burden of disease, with possible contributions from suboptimal dopaminergic therapeutic response in men. However, motor features of disease evaluated with clinician-based scales in the OFF medication state, as well as biological biomarkers do not show specific sex-related progression patterns.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

          Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications. © 2010 Movement Disorder Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Parkinson Progression Marker Initiative (PPMI).

            The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics. Copyright © 2011 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale.

              Formulas were developed to define tremor dominant (TD) and postural instability/gait difficulty (PIGD) phenotypes of Parkinson's Disease (PD) using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). TD and PIGD designations, based on the original Unified Parkinson's Disease Rating Scale (UPDRS), provided useful designations for classifying different phenotypes of PD. With the advent of the MDS-UPDRS, a valid set of calculations for these phenotypes is needed. UPDRS and MDS-UPDRS scores were collected on 877 PD patients. TD/PIGD scores were calculated using the UPDRS formula for all patients. Comparable TD and PIGD items from the MDS-UPDRS were used to calculate new ratios. Data were analyzed using receiver operating characteristic models. The new MDS-UPDRS TD/PIGD ratios accounted for a significant area under the curve compared with the UPDRS classification. Optimal sensitivity and specificity were obtained with MDS-UPDRS cutoff scores of ≥1.15 for TD classification and ≤0.90 for PIGD. The development of comparable and valid PIGD and TD scores from the MDS-UPDRS provides a clear method for clinicians and researchers to transition from the original UPDRS to the new MDS-UPDRS in categorizing patients with different clinical phenotypes. © 2013 Movement Disorder Society. Copyright © 2013 Movement Disorder Society.
                Bookmark

                Author and article information

                Journal
                J Parkinsons Dis
                J Parkinsons Dis
                JPD
                Journal of Parkinson's Disease
                IOS Press (Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands )
                1877-7171
                1877-718X
                4 November 2021
                21 January 2022
                2022
                : 12
                : 1
                : 421-436
                Affiliations
                [a ]Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Neuroscience Section, University of Salerno , Italy
                [b ]Department of Biostatistics, The University of Iowa , Iowa City, IA, USA
                [c ]Department of Neurology, Icahn School of Medicine at Mount Sinai and Mount Sinai Beth Israel, New York, NY, USA
                [d ]Department of Neurology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA
                [e ]Weill Institute for Neuroscience, Department of Neurology, University of California–San Francisco , & Parkinson’s Disease Research Education and Clinical Center, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA
                [f ]Department of Neurology, University of Alabama at Birmingham , Birmingham, AL, USA
                Author notes
                [ § ]

                Statistical analysis was conducted by David-Erick La Fontant, Chelsea Caspell-Garcia, Christopher Coffey, Hyunkeun Ryan Cho and Elliot L Burghardt from the Department of Biostatistics, The University of Iowa, Iowa City, IA, USA.

                [* ]Correspondence to: Amy W. Amara, MD, PhD, University of Alabama at Birmingham SC360A, 1720 2nd Ave S., Birmingham, AL 35294-0017, USA. E-mail: aamara@ 123456uabmc.edu .
                Article
                JPD212892
                10.3233/JPD-212892
                8842783
                34744052
                39484a03-2434-49fc-8b45-9787d747da6e
                © 2022 – The authors. Published by IOS Press

                This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 3 October 2021
                Categories
                Research Report

                datscan,motor,non-motor,parkinson’s disease,sex
                datscan, motor, non-motor, parkinson’s disease, sex

                Comments

                Comment on this article